INTRODUCTION
There is much experimental evidence that platelet interaction with vessel wall components is an important part of the normal hemostatic mechanism. Of the vessel wall constituents, the evidence concerning collagen is the best established (1) but there are suggestions that basement membrane (2) and microfibrils 1 may also react with Dr. Nossel is a recipient of Research Career Development Award IK04-HE 46355.
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platelets. Purified collagen fibers cause platelet aggregation in vitro by a series of reactions which include initial adhesion of platelets to collagen and release of adenosine diphosphate by platelets (1, 3) . Conditions quantitatively influencing the development of platelet aggregates include the intensity of the stimulus, and the reactivity of the platelets. In the present study, a previously unrecognized constituent of normal plasma is described which binds to collagen and inhibits platelet adhesion and aggregation. Previous studies presented evidence that the free amino groups of lysine are critical for the platelet aggregating effect of collagen (4) . It was also shown that some materials causing platelet aggregation could be divided into two categories, one dependent for activity on positively charged groups and another on negatively charged groups (5) . The purified plasma inhibitor described in this publication neutralizes the cationic aggregators but not the anionic group.
METHODS
Platelet-rich plasma was collected and prepared as previously described (4) and kept at room temperature until it was tested.2 The blood was anticoagulated with 0.1 volume 4% trisodium citrate or 1% (w/v) heparin (Hynson, Westcott & Dunning, Inc., Baltimore, Md.). Platelet-poor plasma was prepared by centrifuging platelet-rich plasma until the count was less than 100 platelets per mm'. Serum was prepared from platelet-poor plasma as previously described (18) except that the test tubes were not treated with silicone. Saline (0.15 M), buffered with barbital acetate at pH 7.40 was prepared as previously described (6) . Other buffers were made as described by Gomori (7) . Collagen was ex--tracted from human cadaver skin by the Nishihara method as previously described (8) . For platelet aggregation studies, the collagen was suspended in buffered saline using a Duall tissue grinder (Kontes Glass Co., Vineland, N. J.) (4). Succinylated collagen was prepared by treating Nishihara collagen with succinic anhydride by the method of Gustavson as described elsewhere (9) . All the free amino groups on the collagen molecule were succinylated in the preparations tested (9) . Reagent grade chemicals were used throughout 2 Platelets were counted by the Rees-Ecker method (17) .
2168
The Platelet adhesion to collagen was tested by incubating 0.1 ml collagen (20 ltg) with 0.4 ml saline or with 0.4 ml of a partially purified inhibitor preparation for 20 min with constant stirring. 1 ml platelet-rich plasma anticoagulated with disodium EDTA (3.9 mm, 2 mg/1.5 ml in the final mixture) was added and the mixture stirred at 370C for 1 min. The samples were then examined by phase contrast microscopy (magnification X 3200, Zeiss photomicroscope II, Carl Zeiss Inc, New York) and adhesion or absence of adhesion to collagen was noted. The effect of adsorbing serum to and eluting it from collagen was tested as follows: two 50 mg portions of the same batch of collagen were suspended in 7 ml pH 7.4 saline buffer. 200 ml saline was added to one portion termed the control and this batch was then treated in an identical way to the serum-treated collagen. 200 ml serum was added to the other collagen portion termed the serum-treated collagen. After stirring at room temperature for 20 min the collagen batches were centrifuged at 10,000 g for 15 min and the supernatant fluid was decanted. The collagen was resuspended in 10 ml distilled water and separated by centrifugation as described above. The washing with distilled water was repeated for a total of four times. The two collagen preparations were then lyophilized, suspended in saline, and platelet aggregating activity was measured in terms of the original batch of collagen. Each batch of collagen was then dialyzed against pH 7.4 1.5 M saline for 60 hr. The collagen was then separated by centrifugation and washed four times with 1.5 M saline. The two collagen batches were then dialyzed overnight against distilled water, lyophilized, suspended in 15 M saline, and tested for platelet aggregating activity in terms of the original batch of collagen.
The heat stability of the inhibitor was measured by heating 1 ml portions of serum in test tubes to different temperatures for 10 min. The sera were then transferred to an ice bath and inhibitory activity was measured in terms of the activity of a serum portion maintained in the ice bath throughout. The pH stability of the inhibitor was measured by dialyzing 2-ml portions of serum against various pH buffer solutions for 5 hr and then for 16 hr against 0.15 M saline buffered with barbital at pH 7.4. The inhibitory activity of the different serum samples was measured in terms of the activity of a serum portion which had been dialyzed against pH 7.4 buffer for 21 hr. 4-ml serum samples were dialyzed for 22 hr against large volumes of 0.025 M barbital buffer pH 7.4 with varying molarity sodium chloride (0-1 M). The using an SW 39L rotor. 1 ml partially purified inhibitor fraction in saline, buffered at pH 8.6 or serum buffered at pH 8.6 was applied to 4 ml 10-40%o sucrose gradient buffered with barbital at pH 8.6 . After centrifuging three tubes with similar contents, the fluid in each tube was collected in five 1-ml fractions through a pinhole at the bottom of the cellulose acetate tube. The corresponding fractions from each of the three tubes were pooled, lyophilized, reconstituted with 1/3 volume distilled water, and dialyzed for 3 hr against buffered saline before being tested for inhibitory activity. In some of the ultracentrifuge runs, two of the tubes contained a partially purified inhibitor fraction or serum and the third tube contained a molecular weight marker. The following molecular weight markers were used, ovalbumin (45,000), aldolase (158,000), gamma globulin (160,000), thyroglobulin (670,000), all obtained from Mann Research Labs Inc, New York, fibrinogen (330,000) from Dr. R. E. Canfield and 28S ribosomes (1.6 million mol wt) from rabbit reticulocytes from Drs. M. Terada and P. A. Marks. Serum was electrophoresed at pH 8.6 on Pevikon (Pevikon C-870, Mercer Chemical Corporation, New York) as described by Muller-Eberhard and Osterland (11). 4.5 ml serum mixed with an equal volume of 0.1 M pH 8.6 barbital buffer was electrophoresed for 22 hr at 4°C. The block was sectioned and eluted with the starting buffer. The eluates were reduced in volume by air drying, dialyzed against pH 7.4 buffered saline and tested.
Ion exchange chromatography was carried out using DE52 (Whatman, from H. Reeve Angel & Co, Inc, Clifton, N. J.). 5 ml portions from the eluted fractions were pooled, lyophilized, reconstituted with 0.1 volume distilled water, dialyzed against 0.15 M pH 7.4 barbital buffered saline and tested for inhibitor activity. The contents of individual tubes from the active pool were then tested. The sensitivity of the inhibitor to trypsin was tested as follows: 1 ml inhibitor partially purified by DEAE chromatography (specific activity 1.4 tu/mg, protein concentration 3.4 mg per ml) was incubated with 0.1 ml CaCl2 0.114 M and 4 mg trypsin (220 ,i/mg, Worthington Biochemical Corp, Freehold, N. J.) at pH 8.1 for 2 hr at 250C. 9 ml barbital-buffered saline pH 7.4 was added and the mixture ultrafiltered to a volume of 1 ml through an XM 100 Amicon membrane (retains molecules of 160,000 mol wt and greater). Two further 9-ml volumes were added to the retained fluid and filtered through the same membrane. The retained material was then assayed for inhibitory activity as compared with a control sample to which 0.1 ml saline was added in place of trypsin. Protein concentration was measured as described by Lowry, Rosebrough, Farr, and Randall (12) .
RESULTS
Incubation of platelet-poor plasma with collagen resulted in progressive inactivation of the platelet-aggrega-*ting effect of collagen (Fig. la) . Similar results were obtained whether the platelet-poor plasma was anticoagulated with heparin or citrate. Anticoagulation of the platelet-rich plasma with citrate or heparin also did not affect the results. The rate of inactivation of the collagen by plasma was independent of temperature between 4VC and 370C. Using a constant incubation period the degree of inactivation of the collagen was related to the concentration of inhibitor fraction (Fig. lb) or plasma (Table I) . Fractionation of plasma by precipitation with ammonium sulfate gave poor recovery of inhibitory activity. Inhibitory activity was not affected by dialysis against concentrated sodium chloride (to 1 M) but was lost after dialysis against hypotonic solutions (below 0.025 M sodium chloride) at pH 7.4. The inhibitory activity was not adsorbed by celite or barium sulfate but was adsorbed by aluminum hydroxide gel. When tested for thermal stability most of the inhibitory activity was lost after 10 min at 560C and com-, plete inactivation occurred at 60'C. The inhibitor lost activity in 24 hr at 4VC but appeared to be stable at -50'C and was not altered by freezing and thawing up to three times. Exposure to a pH range revealed marked loss of activity below pH 7 but stability at pH 7 The inhibitor was not dialyzable and ultrafiltration of serum indicated that the inhibitory activity was retained by the XM100 membrane in accordance with a molecular weight greater than 100,000. When a partially purified inhibitor fraction or serum was ultracentrifuged on a sucrose density gradient most of the inhibitory activity sedimented at approximately the same rate as fibrinogen but some inhibitory activity sedimented as a larger molecule (Fig. 2) . On Pevikon block electrophoresis the inhibitor migrated with the alpha globulins (Fig. 3) . Partial purification of the inhibitor could be achieved by ion exchange chromatography on diethylaminocellu- The elution of inhibitory activity from DE52 cellulose. Serum was dialyzed against 0.025 M barbital buffer pH 8.6 and applied to a DEAE column equilibrated with the same buffer. The protein was eluted with increasing molarity NaCl buffered with barbital at pH 8.6. The column size was 50 X 2-5 cm and 10 ml fractions were collected.
lose (Fig. 4 , Table II ). Recovery of activity was consistently greater after ion exchange chromatography than in the original plasma. The purified fraction was used to examine aspects of the inhibitory action. Mixture of the inhibitor with platelet-rich plasma suppressed platelet aggregation (Fig. 5 ). This result indicates that in the presence of a sufficiently high inhibitor concentration preincubation with collagen is not necessary to prevent platelet aggregation. Addition of the inhibitor to The Table gives the inhibitory activity, protein concentration, and volumes for the inhibitor recovered by DEAE chromatography described in Fig. 4 . collagen effectively prevented platelet adhesion to collagen (Fig. 6) .
The effect of a number of plasma proteins was tested on the platelet aggregating ability of materials dependent for activity on anionic or cationic groups. The plasma inhibitor neutralized the action of all three cationic materials and of crude connective tissue but was without effect on the anionic aggregators (Table III) . Whole plasma and serum inhibited all the materials to a slight extent. Polylysine (50 sAg) was inhibited to a slight extent by 6 mg Cohn fractions II, IV-4, and V (Table  III) . Neither crystalline albumin or the Cohn fractions tested affected the activity of succinylated collagen. Crystalline albumin neutralized sodium stearate in a 1: 24 molar ratio (95 mg albumin neutralizes 1 mg stearate) and 2 Ag Cohn fraction IV-4 neutralized 7 ig sodium stearate (Table III) . The data on neutralization with albumin accords with the Goodman's (13) finding that albumin has 27 binding sites per molecule for stearate.
DISCUSSION
The result of the experiment shown in Fig. la indicates that platelet-free normal plasma neutralizes the plateletaggregating effect of collagen in a time consuming reaction. The result of the experiment shown in Fig. lb indicates that inhibition depends on the quantity of inhibitory material present. Since the rate of the inhibitory reaction was independent of temperature it is suggested that the reaction between inhibitor and collagen is physical rather than enzymatic. This suggestion is confirmed by the finding that serum-treated collagen remained less active after washing with distilled water but recovered full activity when washed with 1.5 M sodium chloride. On the basis of the results of that experiment it is further suggested that the inhibitor adsorbs to the collagen molecule probably by ionic bonds. Since the purified inhibitor neutralized the activity of all the cationic aggregators tested but did not affect the activity of the anionic aggregators it seems likely that the inhibitor functions by neutralizing the positively charged groups or preventing platelet contact with these groups. In view of the selectivity towards cationic groups it is suggested that the binding site(s) on the inhibitor are anionic in nature. The neutralizing effect of the inhibitor on connective tissue is consistent with Zucker and Borrelli's (10) thesis that collagen is the active constituent of connective tissue.
The nature of the inhibitor has been only partially determined. It does not appear to be a lipoprotein and migrates with the alpha globulins at pH 8.6. The activity is very unstable at acid pH and is completely de- stroyed by trypsin. The results of the ultrafiltration studies suggested a molecular weight greater than 100,-000. The sucrose density gradient ultracentrifugation studies were in accord with a molecular weight in the range of 330,000. In some experiments when partially purified fractions were ultracentrifuged on a sucrose density gradient slight inhibitory activity was also found in the lowermost fraction, but this did not occur with serum ultracentrifugation. When the fractions were frozen and thawed and retested the activity disappeared from the lowermost fraction but was retained in the middle fraction on the gradient. This observation may signify the presence of an additional inhibitory activity of greater molecular size (macroglobulin) which is unstable on freeze-thawing or of reversible polymerization of the inhibitor.
A question arises as to the physiological effect of the inhibitor since in most of the experiments collagen and platelet-free inhibitor were incubated before adding platelet-rich plasma and the opportunity for such preincubation may not exist in vivo. The results of the experiment shown in Fig. 5 indicated that varying quantities of inhibitor mixed with platelet-rich plasma can exert a profound influence on the reaction of collagen with platelets without preincubation. It is therefore conceivable that in vivo an increased plasma inhibitor concentration could inhibit platelet plug formation and so impair hemostasis. Such a phenomenon has been described in a case of IgA myeloma in which a clinical bleeding tendency was ascribed to an increased concentration of the IgA immunoglobulin which inhibited connective tissue-platelet interaction (14) . Conversely it is possible that a lowered inhibitor concentration could favor the development of platelet aggregates in blood exposed to cationic inducers of platelet adhesion and aggregation.
If microfibrils and other materials in vessel walls which may react with platelets depend for activity on free anionic groups then plasma proteins which neutralize anionic groups may be important in regulating platelet reactivity. Packham, Evans, Glynn, and Mustard (15) , showed that solutions containing albumin inhibited platelet adherence to glass tubes and Merrill et al. (16) , and Vroman' found that albumin inhibited platelet adherence to heparin-coated surfaces.
A possible use for inhibitory fractions may be to coat prosthetic materials so as to render them nonthrombogenic. Specific plasma proteins covalently coupled to the materials from which prosthetic devices are made may be a useful method for inhibiting platelet adhesion at least over a limited period.
